date,title,source
Nov-08-18,3 Health Care Stocks Seeing Heightened Activity After Midterms,ACCESSWIRE
Nov-08-18,Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts,Business Wire
Dec-03-18,"Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer",Business Wire
Dec-27-18,4 Healthcare Stocks That Could Test December Highs,ACCESSWIRE
Dec-27-18,Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer,Business Wire
Jan-03-19,Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer,Business Wire
Jan-18-19,"Sesen Bio, Inc. (NASDAQ:SESN): A Fundamentally Attractive Investment",Simply Wall St.
Jan-22-19,Health Stocks Benefitting the Most from Rally,ACCESSWIRE
Feb-25-19,Sesen Bio to Host Conference Call to Review Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial,Business Wire
Mar-04-19,Edited Transcript of SESN earnings conference call or presentation 4-Mar-19 1:00pm GMT,Thomson Reuters StreetEvents
Mar-04-19,Sesen Bio Reports Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial,Business Wire
Mar-06-19,Edited Transcript of SESN earnings conference call or presentation 4-Mar-19 1:00pm GMT,Thomson Reuters StreetEvents
Mar-07-19,"What Kind Of Shareholder Owns Most Sesen Bio, Inc. (NASDAQ:SESN) Stock?",Simply Wall St.
Mar-27-19,Positive Results and New Technology Give Rise to Antibody Dominance,GlobeNewswire
Mar-28-19,Four Healthcare Stocks Getting a Boost on Thursday,ACCESSWIRE
Apr-29-19,Sesen Bio to Host Conference Call to Review First Quarter 2019 Financial Results and Updated Preliminary Data from Phase 3 VISTA Trial,Business Wire
May-01-19,"Will the Good News for Vicinium Continue for Sesen Bio, They Will Tell Investors Soon",ACCESSWIRE
May-13-19,Edited Transcript of SESN earnings conference call or presentation 13-May-19 12:00pm GMT,Thomson Reuters StreetEvents
May-13-19,"Sesen Bio Reports First Quarter 2019 Financial Results and Updated, Preliminary Primary and Additional Secondary Endpoint Data from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer",Business Wire
